Published in Cancer Med on September 19, 2014
The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol (2016) 0.85
The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Can Urol Assoc J (2016) 0.80
Testicular cancer: Optimal management of stage I seminoma in 2015. Nat Rev Urol (2015) 0.78
Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG). World J Urol (2015) 0.77
Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol (2016) 0.76
Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology (2015) 0.75
Management of stage I testicular germ cell tumours. Nat Rev Urol (2016) 0.75
Analysis of the prognosis of patients with testicular seminoma. Oncol Lett (2015) 0.75
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Patterns of care in the management of seminoma stage I: results from a European survey. BJU Int (2012) 3.41
Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol (2005) 2.99
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol (2002) 2.88
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol (2011) 1.73
Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol (2010) 1.65
Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol (2011) 1.64
Predicting metastasized seminoma using gene expression. BJU Int (2012) 1.60
Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys (2012) 1.58
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Discriminating metastasised from non-metastasised seminoma based on transcriptional changes in primary tumours using NGS. Br J Cancer (2014) 1.44
Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.06
Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol (2010) 0.99
Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol) (2009) 0.94
Stage I seminoma: adjuvant treatment is effective but is it necessary? J Natl Cancer Inst (2011) 0.88
Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy? Clin Oncol (R Coll Radiol) (1992) 0.82
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol (2010) 5.44
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Is video-assisted lobectomy for non-small-cell lung cancer oncologically equivalent to open lobectomy? Eur J Cardiothorac Surg (2013) 3.49
Patterns of care in the management of seminoma stage I: results from a European survey. BJU Int (2012) 3.41
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (2004) 3.04
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol (2002) 2.88
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73
The natural history of incidentally detected small renal masses. Cancer (2004) 2.57
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. Int J Radiat Oncol Biol Phys (2012) 2.45
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
Utility of serum tumor markers during surveillance for stage I seminoma. Cancer (2012) 2.05
The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review. Radiother Oncol (2002) 2.04
Information needs of men on androgen deprivation therapy. BJU Int (2011) 2.02
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
Predictive model for survival in patients with advanced cancer. J Clin Oncol (2008) 1.93
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood (2002) 1.89
Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol (2010) 1.87
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int (2011) 1.83
Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol (2013) 1.81
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer (2003) 1.78
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
The Multi Centre Canadian Acellular Dermal Matrix Trial (MCCAT): study protocol for a randomized controlled trial in implant-based breast reconstruction. Trials (2013) 1.75
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res (2007) 1.75
Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985-2005. Arch Pediatr Adolesc Med (2010) 1.73
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology (2010) 1.68
Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.66
Sequelae of treatment in long-term survivors of testis cancer. Eur Urol (2011) 1.64
Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int (2009) 1.62
Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol (2002) 1.61
Is mastectomy superior to breast-conserving treatment for young women? Int J Radiat Oncol Biol Phys (2007) 1.58
Accuracy of survival prediction by palliative radiation oncologists. Int J Radiat Oncol Biol Phys (2005) 1.56
Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys (2005) 1.54
Reducing patient wait times and improving resource utilization at British Columbia Cancer Agency's ambulatory care unit through simulation. Health Care Manag Sci (2009) 1.54
Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. Eur Respir J (2013) 1.53
PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer (2006) 1.52
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer (2010) 1.52
Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era. Radiat Oncol (2011) 1.51
Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol (2008) 1.49
Treatment options, prognostic factors and selection of treatment in stage I seminoma. Onkologie (2006) 1.49
Postmastectomy radiation therapy after immediate two-stage tissue expander/implant breast reconstruction: a University of British Columbia perspective. Plast Reconstr Surg (2014) 1.47
Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys (2007) 1.46
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.45
Predictors of nonconvulsive seizures among critically ill children. Epilepsia (2011) 1.43
No role for routine chest radiography in stage I seminoma surveillance. Eur Urol (2009) 1.42
Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res (2012) 1.41
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Classical clinical trial design in testicular cancer: time to move on. J Clin Oncol (2012) 1.38
Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma (2015) 1.38
A dose-volume histogram analysis of the seminal vesicles in men treated with conformal radiotherapy to 'prostate alone'. Clin Oncol (R Coll Radiol) (2002) 1.37
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.34
The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology (2002) 1.32
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J (2011) 1.31
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer (2009) 1.30
Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys (2007) 1.28
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol (2007) 1.22
Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys (2007) 1.20
A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys (2002) 1.20
Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Can J Urol (2002) 1.19
High-intensity focused ultrasound for prostate cancer: a practice guideline. Can Urol Assoc J (2010) 1.15
Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys (2003) 1.15
Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras. Radiat Oncol (2013) 1.14
A population-based study of the fractionation of postlumpectomy breast radiation therapy. In regard to Ashworth et al. Int J Radiat Oncol Biol Phys (2013) 1.13
Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol (2005) 1.12
An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant (2004) 1.12
Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol (2013) 1.12
Major 30-day complications after radical radiotherapy: a population-based analysis and comparison with surgery. Cancer (2009) 1.10
First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer (2006) 1.09
Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. J Clin Oncol (2008) 1.08
Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer. J Magn Reson Imaging (2012) 1.08
Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem (2005) 1.07
Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.07
Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.07